# An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .

> **NCT01077505** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 16 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **BIOLOGICAL:** albiglutide
- **DRUG:** Oral contraceptive (Brevicon)

## Key facts

- **NCT ID:** NCT01077505
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03-15
- **Primary completion:** 2010-11-24
- **Final completion:** 2010-11-24
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01077505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01077505, "An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01077505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*